Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® for the Treatment of Diabetes

Biocon Biologics Ltd. and Viatris Inc. announced that the US FDA has approved Semglee^® as the first interchangeable biosimilar product under the 351(k) regulatory pathway.